The Cigna GroupNYSE: CI
Health Care · Health Care Services
$280.01
-1.78%
Vol: 1.2M
Research Digest
Friday, June 19, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 18Cigna fell 2.3% on June 17 with no major catalyst; the only fresh disclosure was a minor insider sale by the chief accounting officer on June 16.Neutral▶
The Cigna Group declined about 2.3% on June 17, 2026, closing near $285.22, without a clear single catalyst. The only fresh company-specific item in the window was an insider transaction: chief accounting officer Jamie Kates sold roughly $268,000 of stock on June 16, 2026 — a routine, immaterial-sized sale. There was no new earnings, guidance, M&A, or regulatory news in the last 48 hours; Q1 2026 results (net income $1.7B, $6.26 EPS) and the raised 2026 EPS outlook of at least $30.35 were reported back on April 30. Analyst sentiment remains constructive (consensus Buy, ~$341 average target, 20 buys and zero sells). The bear case centers on a shrinking total customer base (down 2% to 185.5M relationships), high debt leverage, and competitive pressure in National Accounts, but none of that is new in this window.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21No significant overnight updatesNeutral▶
No material news in the last 48 hours. The most recent meaningful news for Cigna was the May 13 BofA Healthcare Conference presentation where COO Brian Evanko reaffirmed 2026 adjusted EPS outlook of at least $30.35.
May 20Cigna reaffirmed its 2026 outlook of at least $30.35 adjusted EPS at the BofA Healthcare Conference, citing a 15% prior-authorization cut and a new rebate-free pharmacy model.Positive▶
On May 13, 2026, Cigna's President and COO Brian Evanko presented at the Bank of America Securities Global Healthcare Conference in Las Vegas, where the company reaffirmed full-year 2026 adjusted income from operations of at least $30.35 per share. Management highlighted Q1 2026 revenues of $68.5 billion and progress on operational simplification, including a roughly 15% reduction in medical prior authorizations and the launch of its rebate-free Signature pharmacy model. The company also declared a $1.56 quarterly dividend and announced $250,000 in philanthropic grants in Memphis. Analyst sentiment remains constructive, with consensus rating Strong Buy and a mean price target of ~$342. Year-to-date, CI shares are up about 8.5%, outperforming the S&P 500.
May 19No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 18Cigna reaffirmed full-year 2026 adjusted EPS outlook of at least $30.35 at BofA Healthcare Conference on May 13, highlighting 15% reduction in prior authorizations and rebate-free pharmacy launch.Positive▶
On May 13, 2026, The Cigna Group's President and COO Brian Evanko presented at the Bank of America Global Healthcare Conference, reaffirming the full-year 2026 outlook for consolidated adjusted income from operations of at least $30.35 per share. Management spotlighted efforts to simplify care, including reducing prior authorizations by roughly 15% and launching a rebate-free Signature pharmacy service model. Q1 2026 adjusted revenues increased 4.7% year-over-year to $68.5 billion, prompting an 8.3% increase in stock value following the prior earnings release. Analyst consensus is Strong Buy with mean price target of $342.05 across 23 analysts (18 Strong Buys, 2 Moderate Buys, 3 Holds). YTD in 2026, CI is up 8.5%, surpassing the S&P 500's 8.1% gain. Quarterly dividend was raised 3.3% to $1.56 per share in February.
May 15Cigna reiterated 2026 adjusted operating income outlook of at least $30.35 per share as executives meet with investors and analysts.Positive▶
The Cigna Group reaffirmed its previously issued 2026 adjusted income from operations outlook of at least $30.35 per share as executives prepared to meet with investors and analysts in the coming weeks. The reaffirmation follows Q1 2026 results that beat expectations and prompted an 8.3% share rally on prior guidance raises. Cigna also announced its appearance at the BofA Securities 2026 Health Care Conference. A previously announced CEO transition is set for July 1, when David Cordani steps down as CEO to become executive chair and COO Brian Evanko takes over. Regulatory pressures and the CEO succession remain key risks; consensus among 23 analysts is Strong Buy with a $342 average price target.
May 14Cigna's COO will present at the BofA Healthcare Conference May 13 after reaffirming 2026 EPS guidance of at least $30.35Positive▶
On May 13, 2026, The Cigna Group's President and COO Brian Evanko presented at the BofA Securities 2026 Health Care Conference in Las Vegas at 12:20 p.m. ET. Cigna reaffirmed its full-year 2026 adjusted income from operations outlook of at least $30.35 per share, following Q1 2026 results showing $68.5 billion in revenue and adjusted EPS of $7.79. The board declared a $1.56 quarterly dividend. Bernstein raised its price target to $371, while shares trade near $300.21 with a 12.65 P/E and a 2.0% dividend yield. The company also published content marking its 230-year history of innovation and announced philanthropic grants totaling $250,000 in Memphis. Some investors remain cautious on regulatory risks.
May 13Cigna shares climb 3.6% to $298 as the group exits ACA exchanges and explores strategic options for EviCore.Positive▶
On May 12 The Cigna Group stock rose 3.6% to $298.49 after the company confirmed it will exit ACA exchanges after 2026 (echoing CVS/Aetna) and is exploring strategic alternatives for EviCore, its medical-review business. The moves follow Q1 2026 revenue of $68.5B (+5% YoY) and adjusted EPS of $7.79, prompting a raised full-year adjusted EPS guide to at least $30.35. Bernstein lifted its price target to $371 from $358 and Truist maintained Buy. On May 11 the company published a 230-year heritage piece signaling brand reset. Risk: regulatory scrutiny on PBMs/ACA exits, CEO transition uncertainty, and pre-market post-print volatility (-3.2%).
May 12Cigna Q1 adjusted EPS of $7.79 beats by 2.2%, raises FY26 guidance to at least $30.35 but exits ACA exchanges affecting 369,000 members in 11 states.Mixed▶
Cigna Group reported Q1 2026 adjusted EPS of $7.79 (beating estimates by 2.2%) on net income of $1.7B and revenue of $68.5B (+5% YoY), with adjusted operating income up 12% and adjusted EPS up 16%. Management raised the FY2026 adjusted EPS outlook to at least $30.35 (from at least $30.25). However, the company announced it is exiting Affordable Care Act marketplaces in 2027, sunsetting individual exchange business by year-end and forcing approximately 369,000 members across 11 states to find new coverage. Cigna is also exploring strategic alternatives (including a sale) for its EviCore claims-review subsidiary. Bernstein raised its PT to $371 (from $358) and Baird raised to $337 (from $306); Truist reiterated Buy. Brian Evanko will succeed David Cordani as CEO on July 1, 2026, with Cordani becoming Executive Chair.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.